Hydromorphone (Dilaudid)

03/03/2010 - "After an average of 43 days of treatment with controlled release hydromorphone, the intensity of momentary pain dropped by 46.5% and that of maximum pain dropped by 41.3%, with the efficacy of the treatment being most pronounced with visceral and somatic pain. "
12/09/2004 - "This observational study confirms the good pain-relieving efficacy of sustained-release hydromorphone together with very good tolerability and very good compliance. "
08/01/2009 - "Safety and efficacy of rapid titration using 1mg doses of intravenous hydromorphone in emergency department patients with acute severe pain: the "1+1" protocol."
04/01/2010 - "This means OROS hydromorphone will be more convenient for elderly patients and may improve adherence, resulting in improved pain relief and quality of life."
12/09/2004 - "[Pain reduced and quality of life improved by sustained-release hydromorphone. "

11/01/2015 - "A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (OROS®) hydromorphone in opioid-naive cancer patients: Results of the Korean South West Oncology Group study."
10/01/2014 - "Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study."
08/01/2012 - "The effectiveness of an opioid rotation to parenteral hydromorphone in advanced cancer patients has never been investigated. "
07/01/2008 - "This pilot, double-blind, controlled, crossover study compared the effects of nebulized hydromorphone, systemic hydromorphone and nebulized saline for the relief of episodic breathlessness in advanced cancer patients. "
05/01/2002 - "Hydromorphone metabolites: isolation and identification from pooled urine samples of a cancer patient."

05/15/2014 - "Among the 40 study dogs, the incidence of vomiting associated with hydromorphone administration was 25%. "
08/01/2012 - "However, findings suggested that hydromorphone can be administered to dogs following orthopedic surgery without a clinically important risk of vomiting or regurgitation."
08/01/2012 - "The method of hydromorphone administration had no apparent effect on the likelihood of dogs vomiting. "
08/01/2012 - "Frequency of vomiting during the postoperative period in hydromorphone-treated dogs undergoing orthopedic surgery."
11/01/2014 - "Dogs were monitored for vomiting and signs of nausea for 30 minutes after hydromorphone administration. "

09/01/2010 - "Efficacy of the sustained-release hydromorphone in neuropathic pain management: pooled analysis of three open-label studies."
01/01/2013 - "Open-label study to evaluate the efficacy and safety of extended-release hydromorphone in patients with chronic neuropathic pain."
01/01/2013 - "Patients with chronic neuropathic pain were safely and effectively converted to and maintained on OROS hydromorphone ER."
03/03/2010 - "The aim of this multicentre, longitudinal investigation was to document the efficacy and tolerability profiles of controlled release hydromorphone in patients with heavy visceral, somatic or neuropathic pain under practical conditions. "
03/03/2010 - "[Controlled release hydromorphone for visceral, somatic and neuropathic pain]."

01/01/2012 - "Nausea was significantly increased in the 10 μg hydromorphone group (46.6%). "
01/01/2001 - "The major reasons for change to hydromorphone were side-effects (cognitive/drowsiness/nausea) on previous therapy. "
09/01/1996 - "The use of hydromorphone was complicated by the onset of intractable nausea and sedation. "
09/15/1994 - "There were no significant differences in overall VAS sedation scores (18 +/- 18 mm vs. 19 +/- 18 mm) and in overall mean VAS nausea scores (12 +/- 15 mm vs. 11 +/- 14 mm) between controlled release hydromorphone and immediate release hydromorphone. "
01/01/2012 - "The analgesic effects of 5 and 10 μg intrathecal hydromorphone provided satisfactory pain relief for 12 h postoperatively and nausea increased significantly in a dose-dependent manner."